Tuberculosis Drug Guide India: NTEP Regimens Explained
First-line and drug-resistant TB regimens under India's NTEP programme, free-drug access through Nikshay, and what a hospital pharmacy needs to stock.
This covers the standard drug-sensitive tuberculosis india regimen and its two-phase structure, how drug-resistant TB treatment differs, the Nikshay platform's role in treatment access and adherence, and what NTEP's free-drug model means for a hospital pharmacy's stocking role.
What is the standard drug regimen for drug-sensitive TB under NTEP?
NTEP's drug-sensitive TB regimen uses four first-line drugs administered as fixed-dose combinations across two treatment phases: a two-month intensive phase with isoniazid, rifampicin, pyrazinamide and ethambutol (HRZE), followed by a four-month continuation phase with isoniazid, rifampicin and ethambutol (HRE). This six-month total course is the programme's standard treatment path for a newly diagnosed, non-resistant case.
Fixed-dose combination formulations, rather than four separate tablets, are the programme's standard dispensing format specifically because combining the drugs into one tablet improves adherence and reduces the risk of a patient inadvertently taking an incomplete drug combination that could contribute to resistance development. This fixed-dose approach is central to how tuberculosis india treatment differs operationally from TB programmes that still dispense first-line drugs as separate tablets.
How does drug-resistant TB treatment differ from the standard regimen?
Drug-resistant TB treatment under NTEP draws from a pool of 13 possible drugs, with the specific regimen composition depending on which first-line drugs the patient's TB strain is resistant to, a determination requiring laboratory drug-susceptibility testing before regimen selection. This is a materially more complex treatment path than the standardised drug-sensitive regimen, both in duration and in the number of drugs involved.
A hospital treating drug-resistant TB cases needs laboratory capacity, either in-house or through a rapid-referral arrangement, to identify the resistance pattern before treatment can even be selected, since drug-resistant TB regimens aren't a single standardised protocol the way drug-sensitive treatment is. The pharmacy supporting a drug-resistant TB case also needs to stock a wider and less predictable drug list than the standard four-drug regimen, since the exact combination depends on the individual resistance pattern.
What is Nikshay, and how does it support TB treatment access?
Nikshay is the national digital case-management platform under NTEP where every diagnosed TB patient is registered, supporting both clinical tracking through treatment and the disbursement of financial support tied to the treatment course. Nikshay Poshan Yojana, the nutritional support scheme tied to this platform, provides ₹500 per month in direct benefit transfer to all types of TB patients for the full duration of treatment.
This registration and financial-support structure exists specifically because TB treatment adherence over a full six-month or longer course is a documented challenge, and Nikshay's tracking function is built to support adherence monitoring rather than simply recording a diagnosis once at intake.
Does NTEP provide TB drugs free of charge, and what does that mean for hospital pharmacies?
NTEP provides free diagnostics and quality-assured TB drugs to all diagnosed patients across government health facilities in India, funded and distributed through the national programme rather than requiring patient purchase.
A private or trust hospital's pharmacy engaging with tuberculosis india patients needs a clear pathway for either dispensing NTEP-supplied drugs directly or referring the patient into the government supply chain, rather than defaulting to standard commercial procurement.
A hospital that isn't integrated with the NTEP drug-supply and Nikshay registration pathway risks either duplicating a cost the patient shouldn't have to bear or missing the adherence-support benefits, including the Nikshay Poshan Yojana payment, that registration unlocks.
Why does daily DOTS-based treatment matter for a hospital's TB patient management?
NTEP's programme is built on daily Directly Observed Treatment, Short-course (DOTS), meaning treatment adherence monitoring is a structural part of the programme's design, not an optional add-on left to patient self-report. A hospital managing TB patients needs a process for supporting and documenting this daily observation requirement, whether through its own staff or coordination with the local NTEP unit.
This adherence infrastructure is precisely why TB treatment interruption from a drug-supply gap is a more serious event than a typical medication stockout; an interrupted course doesn't just delay treatment, it raises genuine resistance-development risk for that specific patient going forward. A hospital treating tuberculosis india patients under this framework should treat any gap in fixed-dose combination availability as an urgent supply issue, not a routine backorder.
How does hospital pharmacy stocking intersect with TB drug leakage risk?
A TB patient whose fixed-dose combination isn't available through the expected channel, whether NTEP supply or hospital pharmacy backup, and who is instead sent to an outside chemist for that dose, breaks exactly the adherence chain the DOTS structure and Nikshay tracking are both built to protect. That gap has consequences well beyond the typical revenue-leakage concern of a single missed sale.
Medyzen's managed hospital pharmacy services are built to keep this kind of critical, adherence-dependent medication reliably available inside the hospital, and our piece on prescription leakage covers the broader continuity-of-care and revenue cost when a prescription, TB or otherwise, walks out the door to an outside chemist instead. Our pharmacy inventory management guide covers the reorder discipline needed to avoid exactly this kind of adherence-breaking stockout on a long-course medication.
Sources
- 1National Tuberculosis Elimination Programme — Directorate General of Health Services, MoHFW, Government of India
- 2National TB Elimination Program (NTEP): at a glance — Journal of the Association of Chest Physicians
- 3Central Drugs Standard Control Organisation — Drugs and Cosmetics Act, 1940 and Rules, 1945
- 4World Health Organization — Tuberculosis — WHO
- 5Indian Council of Medical Research — tuberculosis research and treatment guidance
This article is for informational purposes and is not a substitute for professional medical advice. It describes NTEP's programme structure for hospital and clinical reference; it is not a treatment protocol for any individual patient. Consult the treating physician and local NTEP unit for any specific TB case.
FAQ
Frequently asked questions
Yes, NTEP provides free diagnostics and quality-assured TB drugs to all diagnosed patients through government health facilities, alongside the Nikshay Poshan Yojana's ₹500 per month direct benefit transfer for nutritional support during treatment.
The standard drug-sensitive TB regimen runs six months total: a two-month intensive phase with four drugs (HRZE) followed by a four-month continuation phase with three drugs (HRE). Drug-resistant TB treatment typically takes considerably longer and varies by resistance pattern.
Laboratory drug-susceptibility testing identifies which first-line drugs a specific TB strain is resistant to, and that resistance pattern determines which combination from NTEP's pool of second-line drugs is selected for that patient's regimen.
Nikshay Poshan Yojana is NTEP's nutritional support scheme, providing ₹500 per month in direct benefit transfer to all registered TB patients for the complete duration of their anti-TB treatment.
Private and trust hospitals can engage with the NTEP framework for TB patient registration on Nikshay and access to the free drug supply chain, though the specific integration pathway varies by state and hospital arrangement with the local NTEP unit.
Dr. Priya MenonMBBS, MD (General Medicine)
Consultant Physician (Internal Medicine)
Dr. Priya Menon is a consultant physician in internal medicine, writing on drug classes, side-effect profiles, and evidence-based clinical use for hospital and prescriber audiences.